Home Premarket Biotech Digest: Novartis Earnings, Portola Lawsuits, Celgene's Orphan Drug
 

Keywords :   


Premarket Biotech Digest: Novartis Earnings, Portola Lawsuits, Celgene's Orphan Drug

2015-07-23 11:13:42| Biotech - Topix.net

Xarelto, Eliquis and other anticoagulants that face products liability lawsuits have made deals with Portola, which is developing an antidote. One of the first anticoagulants, warfarin, was used as rat poison for 50 years before it began life as a blood thinner - and the only reason it did that was because a US Army sergeant who tried to kill himself with it was cured when treated with Vitamin K. Moral of the story- if you want to develop an anticoagulant, you better also develop its antidote, or you could bungle your way into multiple lawsuits.

Tags: drug earnings digest biotech

Category:Biotechnology and Pharmaceuticals

Latest from this category

All news

»
30.06Hurricane Beryl Update Statement
30.06Summary for Hurricane Beryl (AT2/AL022024)
30.06Hurricane Beryl Graphics
30.06Hurricane Beryl Forecast Discussion Number 8
30.06Hurricane Beryl Public Advisory Number 8
30.06Hurricane Beryl Wind Speed Probabilities Number 8
30.06Hurricane Beryl Forecast Advisory Number 8
30.06Weekly Recap: Rockline Wins WOW Innovation Award, Hospeco Purchases Nuance Solutions & More
More »